ANIK
Price
$15.77
Change
+$0.17 (+1.09%)
Updated
Jul 13 closing price
Capitalization
209.3M
22 days until earnings call
Intraday BUY SELL Signals
ORGO
Price
$2.27
Change
-$0.13 (-5.42%)
Updated
Jul 13 closing price
Capitalization
292.09M
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIK vs ORGO

ANIK vs ORGO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANIK vs. ORGO commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a Hold and ORGO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (ANIK: $15.77 vs. ORGO: $2.27)
Brand notoriety: ANIK and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIK: 47% vs. ORGO: 68%
Market capitalization -- ANIK: $209.3M vs. ORGO: $292.09M
ANIK [@Pharmaceuticals: Generic] is valued at $209.3M. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $292.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIK’s FA Score shows that 0 FA rating(s) are green whileORGO’s FA Score has 0 green FA rating(s).

  • ANIK’s FA Score: 0 green, 5 red.
  • ORGO’s FA Score: 0 green, 5 red.
According to our system of comparison, ORGO is a better buy in the long-term than ANIK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIK’s TA Score shows that 5 TA indicator(s) are bullish while ORGO’s TA Score has 3 bullish TA indicator(s).

  • ANIK’s TA Score: 5 bullish, 5 bearish.
  • ORGO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ANIK is a better buy in the short-term than ORGO.

Price Growth

ANIK (@Pharmaceuticals: Generic) experienced а -1.62% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was -8.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

Reported Earning Dates

ANIK is expected to report earnings on Aug 05, 2026.

ORGO is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORGO($292M) has a higher market cap than ANIK($209M). ORGO has higher P/E ratio than ANIK: ORGO (16.87) vs ANIK (10.71). ANIK YTD gains are higher at: 64.100 vs. ORGO (-56.178). ORGO has higher annual earnings (EBITDA): 40.2M vs. ANIK (-6.71M). ORGO has more cash in the bank: 91.4M vs. ANIK (41M). ANIK has less debt than ORGO: ANIK (25.7M) vs ORGO (70.9M). ORGO has higher revenues than ANIK: ORGO (513M) vs ANIK (116M).
ANIKORGOANIK / ORGO
Capitalization209M292M72%
EBITDA-6.71M40.2M-17%
Gain YTD64.100-56.178-114%
P/E Ratio10.7116.8763%
Revenue116M513M23%
Total Cash41M91.4M45%
Total Debt25.7M70.9M36%
FUNDAMENTALS RATINGS
ANIK vs ORGO: Fundamental Ratings
ANIK
ORGO
OUTLOOK RATING
1..100
2813
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
4164
P/E GROWTH RATING
1..100
10064
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (46) in the Financial Conglomerates industry is somewhat better than the same rating for ANIK (83) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew somewhat faster than ANIK’s over the last 12 months.

ORGO's Profit vs Risk Rating (100) in the Financial Conglomerates industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's SMR Rating (94) in the Financial Conglomerates industry is in the same range as ANIK (95) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ANIK's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as ORGO (64) in the Financial Conglomerates industry. This means that ANIK’s stock grew similarly to ORGO’s over the last 12 months.

ORGO's P/E Growth Rating (64) in the Financial Conglomerates industry is somewhat better than the same rating for ANIK (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew somewhat faster than ANIK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIKORGO
RSI
ODDS (%)
Bearish Trend 1 day ago
65%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 6 days ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
63%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ANIK
Daily Signal:
Gain/Loss:
ORGO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGRCX31.46N/A
N/A
Invesco Comstock Select C
FLCGX40.60N/A
N/A
Meeder Sector Rotation Retail
FSTBX23.61N/A
N/A
Federated Hermes Global Allocation A
LADPX30.23N/A
N/A
Lord Abbett Developing Growth P
PRVIX61.76N/A
N/A
T. Rowe Price Small-Cap Value I

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-5.42%
ANIK - ORGO
36%
Loosely correlated
+1.09%
PRGO - ORGO
31%
Poorly correlated
-0.49%
AMPH - ORGO
30%
Poorly correlated
+3.04%
ACET - ORGO
29%
Poorly correlated
-3.17%
COLL - ORGO
28%
Poorly correlated
-1.16%
More